PCI Pharma Services has acquired Canadian company Bellwyck Pharma Services to bring its clinical trial services to Canada and continental Europe.

Financial terms of the acquisition have not been disclosed.

Bellwyck provides primary and secondary packaging and labelling services for clinical trial and commercial drugs.

The company’s clinical and commercial supply chain solutions will complement PCI Pharma’s core capabilities, such as clinical trial packaging, labelling and logistics relating to Phase I-IV trials.

Bellwyck will add four facilities to the PCI network in the US, Germany and Canada. This will take PCI’s facilities in North America, Europe and Asia-Pacific to 25, with more than 3,700 employees.

PCI Pharma Services CEO Salim Haffar said: “Their passion for patients, talented team and innovative approach to client challenges is perfectly aligned to our purpose and global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world.

“We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities.”

PCI expects that the acquisition will boost access to its services as Canada and Germany rank third and fourth for the total number of clinical trials globally.

Bellwyck Pharma Services CEO Jeff Sziklai said: “We look forward to helping accelerate the global growth of PCI’s clinical business, leveraging our reputation for innovative, customised clinical trial solutions for our clients.”

In August last year, PCI announced it was investing in a new clinical facility near Dublin, Ireland to increase capabilities and capacity for its clinical services business.

The new facility will support PCI’s global clinical network across its Bridgend, UK, Rockford and San Diego, US, and Melbourne, Australia sites.